Tumor infiltrating lymphocytes and methods of therapy
AssigneesRegents of the University of Minnesota, Intima Bioscience, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsBranden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
Life of this patent
Estimating the term…
Abstract
Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.
Claims12
A method of treating cancer in a human subject in need thereof, said method comprising:
- administering to said human subject a plurality of human lymphocytes that comprise a genomic modification in a target sequence of a cytokine inducible SH2-containing protein gene that suppresses expression of a protein encoded by said cytokine inducible SH2-containing protein gene, and wherein said target sequence comprises SEQ ID NO:
- 77, wherein said human lymphocytes comprise T cells or NK cells, and wherein said genomic modification comprises an indel formation in said target sequence.
Dependencies are inferred from the claim text.